Early in 2014, the U.S. Food and Drug Administration approved tiludronate for intravenous administration in horses with navicular disease. Despite being a relatively new drug used in veterinary medicine, some equine practitioners are already prescribing tiludronate for “off-label” use in horses with other conditions, such as osteoarthritis by injecting the drug directly into the joint rather than using a systemic route of administration.
Read complete article
The Black Label Barrel Race
FeaturedAmerican Paradise Ranch
1148 County Road 3690, Paradise, TX








